Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Te
July 16 2009 - 8:22AM
PR Newswire (US)
BALTIMORE, July 16 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company
engaged in the development of advanced preclinical platforms and
tumor specific data to enhance the value of oncology drugs, has
established a collaboration with Do-Coop Technologies Ltd. of
Israel for development of a more soluble form of SG410, its
Benzoylphenylurea (BPU) sulfur analog compound. SG410, an
in-licensed compound, is the first agent in Champions' drug
development pipeline. Using Neowater , a novel proprietary
water-based nanotechnology, Do-Coop has been able to improve the
solubility and activity of SG410. SG410 is an antimitotic inhibitor
that was shown in Biomerk Tumorgraft models to target microtubule
associated protein tau (MAPT) deficient tumors with promising
results as compared to a currently marketed and leading
chemotherapeutic drug. These antimitotic inhibitors target MAPT
(Microtubule-Associated Protein Tau) deficient tumors. In both in
vitro and in vivo models, SG410 has demonstrated promising activity
against prostate and pancreatic cancer. "We are excited to work
with this innovative technology that enables us to move SG410 into
Biomerk Tumorgraft testing and determine its optimal clinical
application," said Doug Burkett, Ph.D., President of Champions
Biotechnology, Inc. "We expect to have early Biomerk Tumorgraft
results for SG410 by the end of 2009. Also, following nearly a year
of efforts to build our oncology drug pipeline we expect to
in-license additional drugs in the near future; SG410 is
anticipated to be the first of many in-licensed compounds to enter
Biomerk Tumorgraft evaluation. Our Biomerk Tumorgraft technology
enables identification of the most promising development path for
the compound in terms of indication, drug combination, and target
patient populations. Studies suggest that evaluations of compounds
through Biomerk Tumorgrafts will lead to more efficient and
successful clinical development." Under the terms of the agreement,
Do-Coop will receive development milestones and royalties based
upon the clinical success of the compound. "We are delighted to
work with Champions and its groundbreaking Biomerk Tumorgraft
platform," said Eran Gabbai, President and CTO of Do-Coop. "This
technology should change the way in which cancer drugs are
developed." For more information regarding Champions
Biotechnology's growing business and recent news, please visit
http://www.championsbiotechnology.com/. About Champions
Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the
development of advanced preclinical platforms and tumor specific
data to enhance and accelerate the value of oncology drugs. The
Company's Preclinical Platform is a novel approach based upon the
implantation of primary human tumors in immune deficient mice
followed by propagation of the resulting engraftments (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological
characteristics of the original human tumor. Early studies suggest
that unlike traditional xenografts, these Tumorgrafts closely
reflect human cancer biology and their response to drugs is
predictive of clinical outcomes in cancer patients. Champions
Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic
candidates. As drugs progress through early stage development, the
Company plans to sell, partner or license them to pharmaceutical
and/or biotechnology companies, as appropriate. The Company also
offers its predictive preclinical platform and tumor specific data
to physicians for personalized patient care and to companies for
evaluation of oncology drugs in models that integrate prognostic
testing with biomarker discovery.
http://www.championsbiotechnology.com/http://www.personalizedcancertreatment.com/
About Do-Coop Technologies Ltd. Do-Coop Technologies Ltd.
specializing in manufacturing and commercialization of its own
novel and proprietary water-based nanotechnology, branded as
Neowater . Neowater displays a clear shift in water known physical
properties due to the unique organization and interaction between
water, suspended nanoparticles and carbon dioxide. Do-Coop focuses
its effort in improving Pharmaceutical and Bio-Pharma applications
within the life science industry. Due to its novelty, Neowater can
be utilized in various applications. Neowater offers better
bioavailability, efficacy, stability, sustained release, and
toxicity reduction of the formulation. With Do-Coop's technology,
pharmaceutical companies will achieve new and extended IP, an
enhanced pipeline, significant cost reduction, and faster time to
market by allowing researchers to use the same delivery system from
in vitro to in vivo research, avoiding a key factor in late-stage
failure. Biotech companies can benefit from enhanced protein
stability, cell growth clonability and secretion, by using Neowater
-based media. Do-Coop's business model is licensing Neowater for
various applications via technology transfer.
http://www.docoop.com/ This press release contains "forward-looking
statements" (within the meaning of the Private Securities
Litigation Act of 1995) that inherently involve risk and
uncertainties. Champions Biotechnology generally uses words such as
"believe," "may," "could," "will," "intend," "expect,"
"anticipate," "plan," and similar expressions to identify
forward-looking statements. One should not place undue reliance on
these forward-looking statements. The Company's actual results
could differ materially from those anticipated in the
forward-looking statements for many unforeseen factors. See
Champions Biotechnology's Form 10-KSB for the fiscal year ended
April 30, 2008 for a discussion of such risks, uncertainties and
other factors. Although the Company believes the expectations
reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are
made, and Champions Biotechnology's future results, levels of
activity, performance or achievements may not meet these
expectations. The Company does not intend to update any of the
forward-looking statements after the date of this press release to
conform these statements to actual results or to changes in
Champions Biotechnology's expectations, except as required by law.
DATASOURCE: Champions Biotechnology, Inc. CONTACT: James Carbonara,
The Investor Relations Group, Inc., +1-212-825-3210 or Public
Relations: Susan Morgenbesser or Janet Vasquez, +1-212-825-3210 Web
Site: http://www.championsbiotechnology.com/
Copyright